Epithelial ovarian cancer
Conditions
Interventions
Test group:Olaparib + Apatinib
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Female patients aged 18 to 75 years old; 2. Pathologically confirmed as platinum-sensitive recurrent ovarian cancer with a recurrence time of >= 6 months; 3. Previously received platinum-based chemotherapy and achieved complete response (CR) or partial response (PR) after chemotherapy; 4. ECOG performance status score of 0-1, with an expected survival of at least 3 months; 5. Good major organ function: normal blood routine, liver and kidney function (such as liver enzymes, creatinine, etc. meeting the requirements of the trial); 6. Signed informed consent, voluntarily participating in this trial, and able to cooperate with treatment and follow-up.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of severe allergic reactions to olaparib, apatinib or their components; 2. Uncontrolled hypertension (systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg) or other serious cardiovascular diseases; 3. History of other malignant tumors (except for those cured for more than 5 years); 4. Patients with central nervous system metastasis or untreated brain metastasis; 5. Severe gastrointestinal dysfunction, such as inability to take oral medication, gastrointestinal perforation or intestinal obstruction; 6. Active hepatitis or other serious infectious diseases; 7. Pregnant or lactating women, or women of childbearing age who cannot take effective contraceptive measures during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Improvement in quality of life;Disease control rate;Incidence and severity of adverse events; | — |
Countries
China
Contacts
Public ContactDongdong Ji
Anqing Municipal Hospital
Outcome results
None listed